The aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This will be assessed using a 5-year cost-utility analysis based on data from the clinical trial and the National Health Data System (NHDS).
Male.
Age ≥ 18 years
ECOG (Eastern Cooperative Oncology Group) performance status 0-2
Histologically proven prostate adenocarcinoma, not previously treated
Presence of nodal or distant metastases
Stage T4.
Prostate volume > 80 cm3.
IPSS >19/35.